Brolucizumab: Will it Make a Differance

Related

• 

  Open-Label Study Evaluating the Effects of the CCR3 Antagonist ALK4290 in Patients With Neovascular AMD Refractory to Anti-VEGF Therapy

  Michael W. Stewart, MD

  Annual Meeting Talks

  2019

• 

  Ethics in Retina: A Discussion on the Ethical Considerations in Industry Relationships and Informed Consent

  Nancy M. Holekamp, MD, FASRS

  J. Michael Jumper, MD, FASRS

  Paul Chan

  Adrienne W. Scott, MD, FASRS

  Webinars and Journal Clubs

  2017

• 

  Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema

  Thomas A. Ciulla, MD, MBA, FASRS

  Updates from the Field

  2017